Navigation Links
Anxiety Disorders & Depression Treatment Market Worth $18.3 Billion by 2025: Grand View Research, Inc.
Date:1/23/2017

SAN FRANCISCO, January 23, 2017 /PRNewswire/ --

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

Continue Reading
Grand View Research Logo
Grand View Research Logo

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757)

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Browse full research report with TOC on "Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market

Further key findings from the study suggest: 

  • Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment's growth is expected to wane
  • Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants
  • On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years
  • Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
  • Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
  • Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
  • North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
  • Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
  • The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Browse related reports by Grand View Research: 

Grand View Research has segmented the anxiety disorders and depression treatment market by product, indication, and region:

  • Anxiety Disorder and Depression Treatment Product Outlook (Revenue, USD Million, 2014 - 2025)
    • Antidepressant drugs
      • SSRIs
      • SNRIs
      • TCAs
      • MAOIs
      • Atypical Antipsychotics
      • Benzodiazepines
      • Anticonvulsants
      • Beta-Blockers
      • Others
    • Therapy & Devices
      • Fischer Wallace Stimulator
      • TMS
      • DBS
      • VNS
      • ECT
      • CBT
      • Others
  • Anxiety Disorder and Depression Treatment Indication Outlook (Revenue, USD Million, 2014 - 2025)
    • MDD
    • OCD
    • Phobias
    • Others
  • Anxiety Disorder and Depression Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • The Middle East and Africa
      • South Africa

Read Our Blog - Anxiety Disorders and Depression Treatment Market: Expected To Witness Steady Growth

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com


Web: http://www.grandviewresearch.com 


'/>"/>
SOURCE Grand View Research, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Breakthrough in Brain Surgery: Asleep DBS Can Relieve Fear and Anxiety Surrounding Surgery
2. Anxiety Disorders Therapeutic Pipeline Review H1 2015
3. Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
4. Now, a Whole New View About Managing Anxiety - Special Sunglasses
5. PA Wolf Administration Officials Release Safe Prescribing Guidelines for Anxiety and Insomnia Medications to Help Curb Overdose Risk
6. Alternatives Available Nationwide to Addictive Benzodiazepines for Anxiety
7. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
8. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
9. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
10. Boston Scientific Announces Collaboration with Pelvic Floor Disorders Network to Study Treatment Strategies for Uterine Prolapse
11. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/13/2017)... --  OrthoAtlanta has been named the official orthopedic and ... for the 2018 College Football Playoff (CFP) National Championship to ... in Atlanta, Georgia . OrthoAtlanta is proud ... participating in many activities leading up to, and including the ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
Breaking Medicine News(10 mins):